Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model

Jin Myung Choi (✉ choijm1@naver.com)

Chonnam National University Hwasun Hospital <https://orcid.org/0000-0002-1678-2671>

Sa-Hoe Lim

Chonnam National University Hwasun Hospital

Zhi-Peng Liu

Chonnam National University Hwasun Hospital

Joon Haeng Rhee

Chonnam National University Medical School

Mee Sun Yoon

Chonnam National University Hwasun Hospital

Jung-Joon Min

Chonnam National University Hwasun Hospital

Shin Jung

Chonnam National University Hwasun Hospital <https://orcid.org/0000-0003-2587-1243>

Research Article

Keywords: Glioblastoma, Immunotherapy, EGFRvIII, Flagellin, Adjuvant

Posted Date: November 18th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1063322/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Purpose

Glioblastoma (GBM) is the most aggressive type of brain tumor with heterogeneity and strong invasive ability. Treatment of GBM has not improved significantly despite the progress of immunotherapy and classical therapy. Epidermal growth factor receptor variant III (EGFRvIII), one of GBM-associated mutants, is regarded as an ideal therapeutic target in EGFRvIII-expressed GBM patients because it is a tumor-specific receptor expressed only in tumors. Flagellin B (FlaB) originated from *Vibrio vulnificus* is known as a strong adjuvant that enhance innate and adaptive immunity in various vaccine models. This study performed whether FlaB synergistically could enhance the anti-tumor effect of EGFRvIII peptide (P_{EGFRvIII}).

Methods

EGFRvIII-GL261/Fluc cells were used for glioblastoma-bearing mouse brain model and cell-bearing mice were inoculated with PBS, FlaB alone, P_{EGFRvIII} alone, and P_{EGFRvIII} plus FlaB. Survival rate through tumor growth was investigated by MRI. T cell population was examined by flow cytometry analysis. Both cleaved caspase-3 and CD8+ lymphocytes were shown by immunohistochemistry (IHC) staining.

Results

The P_{EGFRvIII} plus FlaB group showed delayed tumor growth and increased survival rate when compared to other treatment groups. As an evidence of apoptosis, cleaved caspase-3 expression and DNA disruption were more increased in the P_{EGFRvIII} plus FlaB group than in other groups. In addition, the P_{EGFRvIII} plus FlaB group showed more increased CD8+ T cells and decreased Treg cells than other treatment groups in the brain.

Conclusion

FlaB can enhance the anti-tumor effect of P_{EGFRvIII} by increasing CD8+ T cell response in a mouse brain GBM model.

Introduction

Glioblastoma (GBM), the most common primary malignant brain tumor in adults, has a low overall survival (OS, < 15 months) after its diagnosis [1]. Up to now, treatments for patients with GBM mainly depend on common classical methods such as surgery, radiation, and chemotherapy without leading to much improvement [2]. Microenvironment of GBM has characteristics of a cold tumor that was formed the absence of T cell infiltration and the induction of immune suppressive cells such as regulatory T cell,

M2 type macrophage, and myeloid derived suppressor cells (MDSC) in tumor. Cytokines secreted from immune-suppressive cells such as transforming growth factor- β (TGF- β) and interleukine-10 (IL-10) can inhibit effector T cell and promote tumor growth [3]. Thus, many research groups have recognized the necessity of immunotherapy for GBM. The purpose of using immunotherapy for GBM treatment is to induce tumor suppression by changing the tumor microenvironment from 'cold' to 'hot' through increasing cytotoxic T cells, M1 type macrophages, and APC while reducing Treg. To induce change of the microenvironment, many researchers are developing various immunotherapies such as tumor-specific peptide, dendritic cell (DC) vaccine, chimeric antigen receptor (CAR)-T cell, and checkpoint inhibitors [4].

Epidermal growth factor receptor variant III (EGFRvIII), one of GBM-associated mutations, is a variant of EGFR with deletion of amino acids 6-273, leading to the deletion of EGFR extracellular domain (exon 2 to 7) [5]. It is tumor-specific receptor that is only expressed on the surface of tumor cells. It is not expressed on the surface of normal cells. Approximately 30% of patients with GBM express the EGFRvIII gene [6]. Thus, EGFRvIII is an ideal target of immunotherapy for EGFRvIII-expressing GBM patients including breast, ovarian, and glial tumors [7]. Until now, several peptide-based immunotherapies targeting EGFRvIII have been subjected to both preclinical and clinical trials. In preclinical trials, Heimberger et al. have reported that PEP-KLH vaccination can generate potent anti-tumor effects against subcutaneous and intracerebral tumors [8]. Wu et al. [9] have demonstrated that EGFRvIII-derived cytotoxic T lymphocyte (CTL) epitopes restricted by HLA A0201 (MHC class I) can induce cytotoxic immune response and kill glioma cell in gliomas. In clinical trials, rindopepimut (CDX-110) has been administrated to newly diagnosed GB patients. The safety and efficacy of rindopepimut in Phase I and Phase II trials have been confirmed [10, 11]. In phase 1 clinical trial, PFS and OS of patients with rindopepimut after resection and radiotherapy was 6.8 months and 18.7 months. In phase 2 clinical trial, PFS and OS of patients with rindopepimut after radiotherapy and concurrent TMZ was 14.2 months and 26 months vaccination after radiotherapy and concurrent TMZ. [12].

Flagellin, an agonist of toll-like receptor 5 (TLR5), is known as a potential adjuvant that can induce innate and adaptive immune responses of host cells [13–15]. Flagellin administrated to mice by IN injection showed colocalization with putative dendritic cells and increased TLR5-expressing cells in cervical lymph nodes [16]. Cai et al. [17] have reported that flagellin can suppress cell proliferation and tumor growth by activating TLR5 on breast cancer cells. Rhee et al. [18] have demonstrated that flagellin could inhibit tumor growth through its strong antitumor activity in colon cancer. Nguyen et al. [19] have also reported that flagellin can enhance tumor antigen (TA) - specific CD8⁺ T cell immune response in a therapeutic cancer vaccine model. Dong et al. [20] have described that intracranial injection of flagellin plus tumor cell lysate (TCL) can enhance survival by recruiting CD4⁺ and CD8⁺ T cells to brain tissues in a GL261-bearing C57BL/6 mice GBM model.

In this study, we investigated whether FlagellinB (FlaB) could enhance the anti-tumor immunity in a GL261 glioma mouse brain model when it was combined with a peptide-based immunotherapy. EGFRvIII peptide (P_{EGFRvIII}) used on our experiment is consisted to nine amino acids (LEEKKGNYV) and is known as the best epitope for MHC I binding to induce tumor-specific immune response [9]. Intranasal (IN)

injection more effectively delivered P_{EGFRvIII} and FlaB to the brain than intravenous (IV) or intraperitoneal (IP) injection. P_{EGFRvIII} plus FlaB group inhibited tumor growth and prolonged survival by changing CD8⁺/Treg ratio compared to single treatment groups. Here, we propose that flagellin can enhance anti-tumor effect of peptide through CD8⁺ T cell-mediated immune response in a mouse brain GBM model.

Materials And Methods

Cell line, Flagellin B, and EGFRvIII peptide

Murine GL261 glioma cells transfected with firefly luciferase (GL261/Fluc) were obtained from Dr. Kang (Yonsei-University, South Korea). Human EGFRvIII gene was purchased from a company (Addgene, USA). Human EGFRvIII-overexpressing murine GL261/Fluc glioma cells (EGFRvIII-GL261/Fluc) were manufactured by transfection using a lentivirus vector system obtained from Dr. Min (Chonnam University Hwasun Hospital, South Korea). Cells were cultured in high-glucose Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in a humidified atmosphere with 5% CO₂ at 37°C. Recombinant Flagellin B (FlaB) was provided by Dr. Rhee (Chonnam National University medical school, South Korea). Synthetic P_{EGFRvIII} (9 mer, LEEKKGNVY) was purchased from a company (Anygen, South Korea)

Mouse intracranial (i.c) tumor model treatment condition

EGFRvIII-GL261/Fluc cells were used for preparing a mouse brain tumor model. Seven-week-old female C57BL/6 mice purchased from a company (Orient Bio, South Korea) were anaesthetized with a mixture of zoletil and rompun via intramuscular (i.m) injection. A burr hole was drilled on the surface at 2 mm posterior and 2 mm right from the bregma. Then 2 x 10⁵ of cells (2 ul) were stereotactically injected into a depth 3 mm of the right hemisphere with a sterile 10 ul Hamilton syringe. After injection into the brain, the small hole was sealed with bone wax and sutured by scalp. According to the treatment schedule, mice were treated and divided into the following four groups: Control (PBS), FlaB alone, EGFRvIII peptide (P_{EGFRvIII}) alone, and P_{EGFRvIII} plus FlaB. The detailed treatment schedule is presented in Fig. 3a and 4a.

Tumor formation and delivery of synthetic Ce6-P_{EGFRvIII} and FlaB

Tumor images of mice were obtained using an animal magnetic resonance imaging (MRI) machine (M7TM compact MRI scanner). Mice were anesthetized with a mixture of zoletil and rompun. Enhancer (Magnevist, BAYER, Germany) was injected into the tail vein for tumor identification. Tumor volume was calculated using an Oxix Lite ver.12.0.1 software. P_{EGFRvIII} conjugated with chlorin e6 (Ce6) was prepared to investigate the delivery of peptide into the brain. For preparation of Ce6- P_{EGFRvIII}, 6 mg Ce6, 1.92 mg EDTA, and 1.15 mg N-hydroxysuccinimide (NHS) were mixed in 1 ml dimethyl sulfoxide (DMSO). This solution was incubated at room temperature (RT) for 6 h reaction by stirring in a dark condition and then mixed with 10 mg peptide in 2 ml PBS. The mixed solution was incubated at RT for 12 h reaction by stirring in a dark condition. The mixture was transferred into a dialysis membrane and dialyzed in 1 L DW

for 1 day. After dialysis, Ce6-P_{EGFR^{VIII}} was used for administration. A mixture of Ce6-P_{EGFR^{VIII}} and FlaB (total 20 μ l) was injected into the intranasal channel for delivering P_{EGFR^{VIII}} and FlaB to the brain. To identify movement of P_{EGFR^{VIII}} and FlaB, brains of sacrificed mice were extracted at 4 h after injecting the mixture. Fluorescence signals of Ce6-P_{EGFR^{VIII}} were detected with an in vivo imaging system (IVIS) spectrum (PerkinElmer). Pseudo-color images indicating photon counts were analyzed using Living Image software v. 4.7.2 (PerkinElmer).

Immunofluorescence and immunohistochemistry staining

Extracted mice brains were fixed in 4 % formaldehyde solution. Hematoxylin and Eosin (H&E) stained and paraffin-embedded slides were prepared by Department of Pathology, Chonnam University Hwasun Hospital. For immunofluorescence (IF) staining of FlaB, paraffin-embedded specimens were dewaxed in xylene for 15 min, hydrated with ethanol (100, 80, 60 %) for 10 min each, and then washed with distilled water for 10 min. Specimens were soaked in EnVision FLEX target retrieval low pH solution at heated with high pressure for 15 min to perform heat-mediated antigen retrieval. After natural cooling, endogenous peroxidase activity was quenched with a peroxidase-blocking solution (Dako) for 30 min. After PBST (1xPBS+0.5 % Tween20) washing for 5 min three times, nonspecific sites were blocked with antibody diluent solution (Dako) for 30 min. Mouse anti-FlaB (1:200) was used as primary antibody for FlaB detection. Anti-mouse Alexa Fluor 488 (Green, 1:200, Invitrogen) for FlaB was used as secondary antibody. 4',6-diamidino-2-phenylindole (DAPI) staining was performed as counter staining. Samples were mounted with 4', 6-diamidino-2-phenylindole/Antifade. Images of fluorescent immunolabeled sections were obtained using a fluorescence microscope. For immunohistochemistry (IHC) staining, slides were proceeded with a bond primary refine detection kit (Leica biosystems) following the manufacturer's protocol using Leica Bond. Primary antibodies against cleaved caspase-3 (CC-3, 1:1000; Cell Signaling Technology) and CD8a (1:400; Cell Signaling Technology) were used.

Single cell isolation from tissues and flow cytometry

Single immune cells were isolated from mouse brain and lymph node. Extracted organs were mixed with fetal bovine serum (FBS)-free RPMI 1640. Mashed tissues by syringe rubber were passed through a 100- μ m nylon cell strainer with FBS-free RPMI 1640. After centrifugation at 1400 rpm for 5 min at 4 °C, supernatant was discarded. Brain pellet was incubated with 1 μ g/ml DNAase I and 0.05 % collagenase I at 37°C for 45 min with shaking (200 rpm). Aggregated debris was removed by passing through a 70- μ m nylon cell strainer. After centrifugation at 1400 rpm for 5 min at 4 °C, the pellet was resuspended in 5 mL of 30% Percoll (GE) and overlaid on the top of a gradient containing 5 mL of 75% Percoll solution. The gradient was centrifuged at 2000 rpm for 20 min at RT. Cells were collected from the middle interface of Percoll solution and washed once with fluorescence-activated cell sorting (FACS) buffer. Procedure for single cell isolation from lymph node was the same except for enzyme and Percoll gradient. After cell counting, cells were transferred into a 96-well microplate. For surface staining, cells were incubated with the following antibodies at 4 °C for 30 min: live/dead (1:1000; BD), Pacific Blue-CD3(1:300; BD), PE-CD4 (1:300; BD), APC-CD8 (1:300; BD). For intranuclear staining, cells were incubated

at 4 °C with permeabilization solution (Fixation 1: permeabilization 3, eBioscience) for 60 min. After centrifugation at 4 °C and 1400 rpm, the supernatant was discarded and cells were incubated with diluted PE-Foxp3 (1:300; BD eBioscience) at 4 °C for 20 min.

Statistical analysis

All statistical analyses were performed using GraphPad Prism 6.0 software. Statistical significance was considered at P value < 0.05. Survival analysis was performed using the Kaplan-Meier method and the log-rank test. All data are expressed as means $\pm$ standard error of the mean (SEM).

Results

Characterization of EGFRvIII-GL261/Fluc cells

Human EGFRvIII gene was transfected into GL261/Fluc cells using a lentiviral vector system to generate EGFRvIII-GL261/Fluc cells. We first examined whether EGFRvIII was expressed on EGFRvIII-GL261/Fluc cells. As shown in Fig. 1, EGFRvIII was identified by the fluorescence signal (green) in EGFRvIII-GL261/Fluc cells using immunofluorescence staining (Fig. 1a). Position of EGFRvIII on cells was confirmed through fluorescence signal (red line) by flow cytometry (Fig. 1b). In addition, cells were treated without or with LY294002 (PI3K inhibitor) to check whether EGFRvIII properly activated downstream signals such as PI3K and AKT. Phosphorylation levels of PI3K and AKT were decreased by LY294002 (Fig. 1c). These results indicate that EGFRvIII was expressed on the cell surface and its downstream signals were functionally operated.

Delivery Of P And Flab To Mouse Brain Tumor

Ce6- P_{EGFRvIII} was prepared as described in the method to identify its movement to mouse brain tumor. Ce6- P_{EGFRvIII} was administered by three injection methods (intranasal or IN, intravenous or IV, and intraperitoneal or IP) to optimize the delivery condition of peptide to the mouse brain tumor model. After extraction of mouse brain, signals of Ce6- P_{EGFRvIII} on the brain were investigated at wavelength between exciting wavelength of 660 nm and emission wavelength of 700 nm with an IVIS spectrum. As shown in Fig. 2a and 2b, we identified quantitatively that Ce6- P_{EGFRvIII} signals by IN injection were detected stronger than those by IV or IP injection. After that, administration of Ce6- P_{EGFRvIII} and FlaB was proceeded by IN injection following the treatment schedule. Tumor formation was verified by MRI and H&E staining at 2 weeks after tumor cell implantation (Fig. 2c). Signals of Ce6- P_{EGFRvIII} in the brain were identified at the same region as the tumor site. FlaB was also confirmed to locate near the brain tumor by IF staining (Fig. 2c).

P_{EGFRvIII} with FlaB enhances proportion of CD8+ T cells in brain and lymph node

FlaB mediates immune response through activation of TLR5-positive immune cells to tumor in host [13–15]. We investigated population of T lymphocytes to identify the role of FlaB in immunotherapy using a GBM mouse brain tumor model. After cell implantation into the brain, immunizations were performed according to the treatment schedule (Fig. 3a). T cell population in the brain and lymph node was analyzed with isolated single cells by flow cytometry. In the brain, between control, FlaB alone, and P_{EGFRvIII} alone group showed no significant difference in percentage of CD4+ or CD8+ cells in the brain. In contrast, the P_{EGFRvIII} plus FlaB group showed significantly higher percentage of CD8+ cell population than the FlaB alone group ($p = 0.0312$) and the peptide alone group ($p = 0.0235$). CD8+/CD4+ T cell ratio was also increased in the P_{EGFRvIII} plus FlaB group than in the FlaB alone group ($p = 0.0223$) and the P_{EGFRvIII} alone group ($p = 0.0172$) (Fig. 3b-3e). And, the percentage of CD4+Foxp3+ regulatory T cells (Treg) was decreased in the P_{EGFRvIII} plus FlaB group than in the control group ($p = 0.068$) (Fig. 3f and g). CD8+/Treg ratio in the brain was significantly improved in the P_{EGFRvIII} plus FlaB group than in the FlaB and the P_{EGFRvIII} alone group (Fig. 3f). In lymph node, the percentage of CD8+ T cells population was also significantly increased in the P_{EGFRvIII} plus FlaB group than in the FlaB alone group ($p = 0.0262$). However, the proportion of CD4+ T cells showed no difference between the control and treated groups (Fig. 3g and h). These results indicate that P_{EGFRvIII} with FlaB could synergistically induce the population of CD8+ T cells in the brain and lymph nodes.

FlaB enhances therapeutic efficacy of P_{EGFRvIII} in a mouse brain tumor model

At day 9 and day 20 after cell injection based on the study schedule, MRI was performed to determine changes of tumor growth according to treatment (Fig. 4a). Figure 4b shows representative mouse brain MRI on control and treated groups. Tumor change ratio was measured to be 9.58 for the control group, 9.40 for the FlaB alone group, 7.25 for the P_{EGFRvIII} alone group, and 4.13 for the P_{EGFRvIII} plus FlaB group (Fig. 4c). The FlaB alone group exhibited no tumor inhibition effect compared to the control group. The P_{EGFRvIII} alone group showed the inhibited tumor growth of about 25% than the control or the FlaB alone group. The P_{EGFRvIII} plus FlaB group showed inhibited tumor growth of about 65% compared to the control or FlaB alone group. With change of tumor growth, mean survival was enhanced from 34.4 ± 2.9 days in the control group to 36.4 ± 2.3 days in the FlaB alone group, 37 ± 1.8 days in the P_{EGFRvIII} alone group (Fig. 4d), and 46 ± 4.0 days in the P_{EGFRvIII} plus FlaB group. These results revealed that P_{EGFRvIII} with FlaB could improve survival with a delay of tumor growth.

Infiltrated CD8+ T lymphocytes to tumor play a very important role in the anti-tumor effect for various cancers [21]. Thus, we investigated CD8+ lymphocytes and cleaved caspase-3 on tissue sections by IHC staining to determine the relation between CD8+ lymphocytes and tumor cell death for antitumor effect. Immunostaining levels of TIL CD8+ lymphocytes were increased in the P_{EGFRvIII} plus FlaB group compared to those in other groups (Fig. 5a). Expression levels of cleaved caspase-3 as an apoptosis marker were also consistently increased in the P_{EGFRvIII} plus FlaB group, like TIL CD8+ lymphocytes (Fig. 5a). In addition, DNA destruction showed the increased average spot number in the P_{EGFRvIII} plus

FlaB group by using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (Fig. 5b and 5c). These results indicated that tumor cell death in the P_{EGFRvIII} plus FlaB group was induced through increased infiltration of CD8+ lymphocytes.

Discussion

GBM is one of the most difficult cancer for treatment due to its strong invasive and heterogeneous property. Primary GBM is isocitrate dehydrogenase (IDH)-wildtype and is associated with mutations of genes such as *EGFRvIII*, *TERT* promoter, *TP53*, and *PTEN* [22]. Among mutations, EGFRvIII-positive GBM has shown slight increases of PFS and OS by immunotherapy using EGFRvIII peptides in preclinical and clinical trials [10–12, 23, 24]. Adjuvants are usually used to improve the therapeutic effect through immune response boosting of drugs including peptide vaccine. Among various adjuvants, flagellin is known as an adjuvant for immunotherapy that can induce increases of CD4+ and CD8 T+ cells for various cancers including melanoma, colon, and breast cancers [17, 18, 25]. In our study, we hypothesized that FlaB could enhance peptide-based immunotherapy as an adjuvant or an immune-modulator in glioblastoma-bearing mouse brain tumor model. We preferentially administered P_{EGFRvIII} and FlaB by IN injection as it was identified as the most effective delivery method. They were also located in brain tumor tissues. This indicates that P_{EGFRvIII} and FlaB administrated by IN injection can effectively provide an opportunity to interact with immune cells in the brain tumor environment. Although FlaB alone group showed no difference in the effect on tumor growth compared to the control group, peptide plus FlaB inhibited tumor growth more than P_{EGFRvIII} alone and FlaB alone. CD8+ lymphocytes and cleaved caspase-3 were histologically identified to have increased expression in the P_{EGFRvIII} plus FlaB group. This suggests that cleaved caspase-3 for tumor apoptosis and increase of CD8+ lymphocytes might be correlated.

GBM has a 'cold' tumor microenvironment that is formed through immune evasion by immune suppressive factors such as gangliosides, kynurenine, TGF- β , IL-10, vascular endothelial growth factor (VEGF), and immunosuppressive cells such as Treg and MDSC. This tumor microenvironment can inhibit CTL function of tumor-infiltrated T lymphocytes (TILs) and promote tumor growth by triggering T cell aging, tolerance, inability, and exhaustion [26–28]. Among TILs, reduction of CTL-trafficking to the tumor microenvironment and increase of Treg can occur by some factors [29, 30]. Inversely, increase of CTL-trafficking into a tumor is associated with prolonged survival of GBM patients through tumor killing by CTL [31]. In various cancers, CTL is correlated with improvement of anti-tumor response [21, 32–34]. From this point of view, we assume that change of T cell population in brain could influence tumor growth and survival of a GBM mouse model. In our study, the P_{EGFRvIII} plus FlaB group showed increased proportion of CD8+ T cells in mouse brain tumor compared to other groups. However, the proportion of CD4+FoxP3+ regulatory T cells was decreased in the P_{EGFRvIII} plus FlaB group compared to control or single treatment groups. This means that P_{EGFRvIII} plus FlaB can induce the brain tumor microenvironment to have CTL response condition by increasing CD8+ T cells and decreasing Treg. Flagellin can directly interact with CD11c+ and CD3+ immune cells in both vagina and draining genital

lymph nodes (gLNs) in a genital cancer mouse model [15]. Thus, increase of CD8+ T lymphocytes in the brain might enhance cytotoxic T cells by modulating antigen-presenting immune cells in lymph nodes.

Conclusions

In summary, IN injection can efficiently deliver FlaB and P_{EGFRvIII} to the brain. P_{EGFRvIII} with FlaB can induce an increase in CD8+ T cells and a decrease in Treg cells in a brain tumor. The induction of tumor apoptosis through the increase of CD8+ T cells can delay tumor growth and increase survival. Results of our study suggest that FlaB can serve as a potentiated adjuvant for peptide-based vaccine in GBM mouse brain tumor model.

Declarations

Acknowledgments

We thank the support of the National Program for Cancer Control, Ministry of Health & Welfare of the Republic of Korea and thank Jung-Joon Min for providing help with modified cells

Statements and Declarations

Funding

This study was supported by a grant from the National Program for Cancer Control, Ministry of Health & Welfare of the Republic of Korea HA17C0038 (1720120)

Conflicts of interest

The authors declare no conflicts of interest in this work.

Author contributions

Conception, design, and development of methodology: JMC, S-HL, Z-PL, and SJ. Data acquisition, experiment, analysis, and interpretation: JMC, S-HL, Z-PL, JHR, MSY, J-JM and SJ. Writing of the manuscript: JMC, S-HL, and SJ. Study supervision: SJ.

Data availability

The datasets generated in this study are available on request from the corresponding author.

Ethical approval

All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Chonnam National University (CNU IACUC-H-2020-37).

References

1. Surawicz TS, Davis F, Freels S, Laws ER, Jr., Menck HR (1998) Brain tumor survival: results from the National Cancer Data Base. *J Neurooncol* 40: 151-160
2. Scott KA, Dalglish AG, Liu WM (2014) The combination of cannabidiol and Delta9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. *Mol Cancer Ther* 13: 2955-2967 doi:10.1158/1535-7163.MCT-14-0402
3. Nduom EK, Weller M, Heimberger AB (2015) Immunosuppressive mechanisms in glioblastoma. *Neuro Oncol* 17 Suppl 7: vii9-vii14 doi:10.1093/neuonc/nov151
4. Sampson JH, Maus MV, June CH (2017) Immunotherapy for Brain Tumors. *J Clin Oncol* 35: 2450-2456 doi:10.1200/JCO.2017.72.8089
5. Ekstrand AJ, Sugawa N, James CD, Collins VP (1992) Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. *Proc Natl Acad Sci U S A* 89: 4309-4313 doi:10.1073/pnas.89.10.4309
6. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD (1990) Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. *Cancer Res* 50: 8017-8022
7. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. *Cancer Res* 55: 5536-5539
8. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH (2003) Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. *Clin Cancer Res* 9: 4247-4254
9. Wu AH, Xiao J, Anker L, Hall WA, Gregerson DS, Cavenee WK, Chen W, Low WC (2006) Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. *J Neurooncol* 76: 23-30 doi:10.1007/s11060-005-3280-7
10. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, 2nd, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DD (2009) An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. *Mol Cancer Ther* 8: 2773-2779 doi:10.1158/1535-7163.MCT-09-0124
11. Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE, 2nd, Friedman HS, Bigner DD, Sampson JH (2008) Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. *J Immunol Methods* 339: 74-81 doi:10.1016/j.jim.2008.08.004

12. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, 2nd, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DD (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. *J Clin Oncol* 28: 4722-4729 doi:10.1200/JCO.2010.28.6963
13. Mizel SB, Bates JT (2010) Flagellin as an adjuvant: cellular mechanisms and potential. *J Immunol* 185: 5677-5682 doi:10.4049/jimmunol.1002156
14. Honko AN, Mizel SB (2005) Effects of flagellin on innate and adaptive immunity. *Immunol Res* 33: 83-101 doi:10.1385/IR:33:1:083
15. Lee SE, Hong SH, Verma V, Lee YS, Duong TN, Jeong K, Uthaman S, Sung YC, Lee JT, Park IK, Min JJ, Rhee JH (2016) Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer. *Oncoimmunology* 5: e1081328 doi:10.1080/2162402X.2015.1081328
16. Lee SE, Kim SY, Jeong BC, Kim YR, Bae SJ, Ahn OS, Lee JJ, Song HC, Kim JM, Choy HE, Chung SS, Kweon MN, Rhee JH (2006) A bacterial flagellin, *Vibrio vulnificus* FlaB, has a strong mucosal adjuvant activity to induce protective immunity. *Infect Immun* 74: 694-702 doi:10.1128/IAI.74.1.694-702.2006
17. Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D (2011) Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. *Cancer Res* 71: 2466-2475 doi:10.1158/0008-5472.CAN-10-1993
18. Rhee SH, Im E, Pothoulakis C (2008) Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. *Gastroenterology* 135: 518-528 doi:10.1053/j.gastro.2008.04.022
19. Nguyen CT, Hong SH, Sin JI, Vu HV, Jeong K, Cho KO, Uematsu S, Akira S, Lee SE, Rhee JH (2013) Flagellin enhances tumor-specific CD8(+) T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model. *Vaccine* 31: 3879-3887 doi:10.1016/j.vaccine.2013.06.054
20. Dong B, Wang L, Nie S, Li X, Xiao Y, Yang L, Meng X, Zhao P, Cui C, Tu L, Lu W, Sun W, Yu Y (2018) Anti-glioma effect of intracranial vaccination with tumor cell lysate plus flagellin in mice. *Vaccine* 36: 8148-8157 doi:10.1016/j.vaccine.2018.04.053
21. Kmiecik J, Poli A, Brons NH, Waha A, Eide GE, Enger PO, Zimmer J, Chekenya M (2013) Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. *J Neuroimmunol* 264: 71-83 doi:10.1016/j.jneuroim.2013.08.013
22. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors

of the Central Nervous System: a summary. *Acta Neuropathol* 131: 803-820 doi:10.1007/s00401-016-1545-1

23. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD, Heimberger AB (2011) Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. *Neuro Oncol* 13: 324-333 doi:10.1093/neuonc/noq157
24. Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH (2015) A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. *Neuro Oncol* 17: 854-861 doi:10.1093/neuonc/nou348
25. Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Sampson JH (2002) Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. *Neurosurgery* 50: 158-164; discussion 164-156 doi:10.1097/00006123-200201000-00024
26. Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH (2015) Prospects of immune checkpoint modulators in the treatment of glioblastoma. *Nat Rev Neurol* 11: 504-514 doi:10.1038/nrneurol.2015.139
27. Broekman ML, Maas SLN, Abels ER, Mempel TR, Krichevsky AM, Breakefield XO (2018) Multidimensional communication in the microenvirons of glioblastoma. *Nat Rev Neurol* 14: 482-495 doi:10.1038/s41582-018-0025-8
28. Wang H, Zhou H, Xu J, Lu Y, Ji X, Yao Y, Chao H, Zhang J, Zhang X, Yao S, Wu Y, Wan J (2021) Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy. *Cancer Lett* 496: 134-143 doi:10.1016/j.canlet.2020.09.028
29. Bellone M, Calcinotto A (2013) Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. *Front Oncol* 3: 231 doi:10.3389/fonc.2013.00231
30. Slaney CY, Kershaw MH, Darcy PK (2014) Trafficking of T cells into tumors. *Cancer Res* 74: 7168-7174 doi:10.1158/0008-5472.CAN-14-2458
31. Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesoe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiocca EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suva ML, Wucherpfennig KW, Hacohen N, Fritsch EF,

Livak KJ, Ott PA, Wu CJ, Reardon DA (2019) Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. *Nature* 565: 234-239 doi:10.1038/s41586-018-0792-9

32. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science* 313: 1960-1964 doi:10.1126/science.1129139

33. Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH (2007) High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. *Cancer Res* 67: 354-361 doi:10.1158/0008-5472.CAN-06-3388

34. Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH (2013) Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. *Am J Clin Oncol* 36: 224-231 doi:10.1097/COC.0b013e3182467d90

Figures

Figure 1

Characterization of EGFRvIII-GL261/Fluc cells. a Both GL261/Fluc and EGFRvIII-GL261 cells were double-stained with WGA (wheat Germ Agglutinin, red) and EFGRvIII (green). Nuclei was stained with DAPI (blue). b EGFRvIII expression on cell surface was detected with Alex488 by flow cytometry. c EGFRvIII-GL261/Fluc cells were treated without (-) or with (+) LY294002 (PI3K inhibitor) to identify kinetic activity of EGFRvIII. Phosphorylation levels of PI3K and AKT from cell lysates were analyzed by western blotting using p-PI3K p85(Y458) and pAKT(S473) antibodies.

Figure 2

Delivery of PEGFRvIII and FlaB to mouse brain tumor. a Ce6-PEGFRvIII was administrated through different injection methods (intranasal; IN, intravenous; IV, intraperitoneal; IP) and brain was extracted at 4 h after administration. Image of fluorescence of Ce6-PEGFRvIII in brain tumor was obtained using IVIS spectrum at wavelength between 640 nm and 700 nm. b Results are statistically analyzed and average value of total flux (p/s) is shown (n = 3 for each group). **, p < 0.001. c Tumor is identified by MRI and H&E staining at 2 weeks after EGFRvIII- GL261/Fluc cell implantation. Synthetic Ce6-PEGFRvIII and FlaB were mixed and IN injected (total 20 ul) to C57BL/6 mouse. Signals of Ce6-PEGFRvIII in brains were detected by IVIS spectrum. To identify FlaB delivery into the brain, paraffin-embedded tissue slides were prepared. FlaB was detected by IF staining using Alexa 488 (green). Each image represents one of three mice.

Figure 3

Distribution of T lymphocytes in brain tumor and cervical lymph node. a Mice were sacrificed at day 20 of experimental treatment schedule. Mice were intranasally administered with PBS, 5 ug FlaB alone, 15 ug PEGFRvIII alone, or 5 ug FlaB plus 15 ug PEGFRvIII. Immunization was performed 3 times at intervals of 5 days. b-d and f-g After gating CD3+ lymphocytes, distribution of CD8+ and CD4+ T cells in brain tumor was analyzed by flow cytometry. e and h Ratio of CD8/CD4 and CD8 / Treg cells in control and treated

mice groups were estimated. i-k Distribution of CD8+ and CD4+ T cells in cervical lymph node was analyzed by flow cytometry. Statistic results and graphs are presented as mean of three independent experiments (n = 9 in each group). Significant differences are indicated by asterisk: *, p < 0.05; **, p < 0.01.

Figure 4

Tumor growth and survival rate based on experimental treatment schedule. a Survival period of mice was proceeded until 80 days according to study schedule. b T1 images of tumor at 9 days and 20 days by magnetic resonance imaging (MRI) are shown. Image represents one of three mice. c Tumor volume was measured by Osirix Lite v.12.0.1. (n = 3, **: p < 0.01). d Survival rates of mice in four groups: Control (n = 7), FlaB alone (n = 10), PEGFRvIII alone (n = 9), PEGFRvIII plus FlaB (n = 10). Results are presented as

average of three independent experiments. Survival curve was made by the Kaplan-Meier. Statistical significance was determined by log-rank test.

Figure 5

Induction of apoptosis in brain tumor tissues. a Distribution of CD8+ lymphocytes and expression of cleaved caspase-3 in extracted mouse brain tumors after IHC staining. b DNA destruction in brain tumor tissues after TUNEL assay. c Spots were randomly selected from three regions in tissues and counted to obtain average of fluorescence signal. Significant differences are indicated by asterisk: **, $p < 0.01$.